首页> 外文期刊>Antimicrobial agents and chemotherapy. >Pharmacokinetics of LB80331 and LB80317 following oral administration of LB80380, a new antiviral agent for chronic hepatitis B (CHB), in healthy adult subjects, CHB patients, and mice.
【24h】

Pharmacokinetics of LB80331 and LB80317 following oral administration of LB80380, a new antiviral agent for chronic hepatitis B (CHB), in healthy adult subjects, CHB patients, and mice.

机译:在健康成人受试者,CHB患者和小鼠中口服LB80380(一种新的慢性乙型肝炎(CHB)抗病毒药)后,LB80331和LB80317的药代动力学。

获取原文
获取原文并翻译 | 示例
           

摘要

LB80380, a dipivoxil ester prodrug of LB80331 (metabolite, LB80317), is a novel antiviral agent for chronic hepatitis B (CHB). The pharmacokinetics of LB80331/LB80317 were evaluated in two clinical studies and a study with mice. The clinical studies were dose-escalating pharmacokinetic studies with six healthy subjects per single-dose group and six CHB patients per repeated-dose group. The mouse study was designed to measure the amounts of the phosphorylated portions of LB80331 and LB80317 in the liver. In healthy subjects receiving a single dose of LB80380, the plasma level of LB80331 increased as the dose increased. Although a high-fat diet delayed the time to the maximum concentration in plasma (T(max)) of LB80331, the area under the concentration-time curve from time zero to infinity was similar between the subjects in the fasted group and those in the group who consumed a high-fat diet. In CHB patients, the mean T(max) of LB80331 was 1.0 to 2.0 h postdosing at steady state. The steady-state plasma concentration of LB80331 declined in a monoexponential manner, and the apparent elimination half-life was 2.5 to 3.3 h. The steady-state plasma concentration of LB80317 was maximum at 3 to 8 h postdoing and declined in a monoexponential manner; the apparent elimination half-life was 45 to 62 h at the 30- to 240-mg doses, while LB80317 was measurable in plasma only at higher doses of 120 and 240 mg after the administration of the first dose of LB80380. Forty percent of the amount of LB80331/LB80317 in the mouse liver was detected as the phosphorylated form. In conclusion, LB80380 is rapidly absorbed and converted to LB80331. LB80317 has a long half-life at steady-state, supporting the use of a once-daily dosing regimen. The ingestion of a high-fat diet delays the rate of absorption of LB80380 without affecting the extent of absorption.
机译:LB80380是LB80331(代谢产物,LB80317)的二甲吡唑酯前药,是一种新型的抗慢性乙型肝炎(CHB)抗病毒药。在两项临床研究和一项小鼠研究中评估了LB80331 / LB80317的药代动力学。临床研究是剂量递增的药代动力学研究,每个单剂量组有6名健康受试者,每个重复剂量组有6名CHB患者。小鼠研究旨在测量肝脏中LB80331和LB80317磷酸化部分的量。在接受单剂​​量LB80380的健康受试者中,LB80331的血浆水平随剂量的增加而增加。尽管高脂饮食使LB80331达到血浆中最大浓度(T(max))的时间延迟,但空腹组受试者与空腹组受试者的浓度-时间曲线下从零时点到无穷大的面积相似。食用高脂饮食的人群。在CHB患者中,稳定状态下服药后LB80331的平均T(max)为1.0至2.0 h。 LB80331的稳态血浆浓度以单指数方式下降,表观消除半衰期为2.5至3.3 h。 LB80317的稳态血药浓度在用药后3至8 h达到最大值,并以单指数方式下降。在30到240毫克剂量下,表观消除半衰期为45到62小时,而在第一剂量LB80380施用后,仅在更高剂量的120和240毫克下,血浆中的LB80317可以测量。检测到小鼠肝脏中LB80331 / LB80317量的40%为磷酸化形式。总之,LB80380被迅速吸收并转化为LB80331。 LB80317在稳态下具有长的半衰期,支持每天使用一次的给药方案。摄入高脂饮食会延迟LB80380的吸收速率,而不会影响吸收程度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号